|
|
Vaccine Detail
|
PSA:154-163(155L) Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: PSA:154-163(155L) Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007156
- Type: Peptide vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- KLK3
gene engineering:
- Preparation: This is for Prostate Cancer (NCT00109811). A cancer vaccine comprised of a synthetic peptide with an amino acid sequence corresponding to positions 154-163 of the amino acid sequence for prostate-specific antigen (PSA) with a leucine substitution at position 155. Upon administration, PSA:154-163(155L) peptide vaccine may elicit a cytotoxic T-cell response against tumor cells that express PSA (NCIT_C29338).
Each PSA:154–163(155L) peptide 1 mg vial was reconstituted with 1 mL of sterile water for injection. A volume of 1.1 mL of Montanide® ISA 51 was added to the reconstituted peptide vial and mixed with a vortex mixer for 12 minutes to form the water-in-oil emulsion (Kouiavskaia et al., 2009).
- Description: NULL
|
| Host Response |
|
|
| References |
Kouiavskaia et al., 2009: Kouiavskaia DV, Berard CA, Datena E, Hussain A, Dawson N, Klyushnenkova EN, Alexander RB. Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer. Journal of immunotherapy (Hagerstown, Md. : 1997). 2009; 32(6); 655-666. [PubMed: 19483644].
NCIT_C29338: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C29338]
NCT00109811: [https://clinicaltrials.gov/show/NCT00109811/]
|
|
